UBE Corporation · TSE:4208
UBE — Ube Industries — FY2014 Earnings Presentation
29 slides from UBE's earnings presentation, May 12, 2015
Slide 1: FY2014 Consolidated Results, FY2015 Consolidated Forecasts
1 FY2014 Consolidated Results FY2015 Consolidated Forecasts May 12, 2015
Slide 2: Contents
2 Contents ・ FY2014 Consolidated Results ・ FY2015 Consolidated Forecasts ・ Appendix
Slide 3: FY2014 Consolidated Results
3 FY2014 Consolidated Results
Slide 4: Scope of Consolidation
4 Scope of Consolidation - FY2014 Consolidated Results - End of FY2013 End of FY2014 Change Item Notes (A) (B) （B) - （A) + UBE Machinery Thai + Ube Kenzai Corporation Number of + AET LLC consolidated 65 71 6 + AET (USA) LLC subsidiaries + AET (Europe) S.A. + AET (Zhangjiagang) Co., Ltd. (※) Number o
Slide 5: Material Price Environmental Factors
5 Environmental Factors - FY2014 Consolidated Results - （Billion Yen） Impacts on FY2013 FY2014 Change Item Consolidated (A) (B) (B) - (A) OP Income Exchange Rate Yen/$ 100.2 109.9 9.7 0.5 (CIF) $/ｔ 940 820 -120 2.7 Naphtha (Domestic) Yen/KL 67,300 63,400 -3,900 (1.3) Material Price Benzene(ACP) $/ｔ
Slide 6: Major P/L & B/S Items
6 Major P/L ＆ B/S Items - FY2014 Consolidated Results - (Billion Yen) FY2013 FY2014 Change Item (A) (B) (B) - (A) Sales 650.5 641.7 -8.7 Operating income 24.4 24.1 -0.2 Ordinary income 18.6 23.2 4.5 Net income 12.6 14.6 2.0 End of FY2013 End of FY2014 Change Item (A) (B) (B) - (A) Total assets 700.7
Slide 7: Sales by Segment
7 Sales by Segment - FY2014 Consolidated Results - （Billion Yen） FY2013 FY2014 Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain -14.8, Chemicals & Plastics 230.5 215.4 -15.1 Synthetic rubber -0.3 Specialty Chemicals & Specialty products -0.3, Products 63.1 63.2 0.1 Fine chemica
Slide 8: Operating Income by Segment
8 Operating Income by Segment - FY2014 Consolidated Results - （Billion Yen） FY2013 FY2014 Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain -0.6, Chemicals & Plastics 0.8 1.1 0.3 Synthetic rubber 0.9 Specialty Chemicals & Specialty products -1.6, Products -0.4 -2.2 -1.8 Fine che
Slide 9: Analysis of Operating Income
9 Analysis of Operating Income - FY2014 Consolidated Results - （Billion Yen） Operating Income Segment Change FY2013 FY2014 Sales Fixed Price Others (A) (B) (B) - (A) *1 Volume Cost *2 Chemicals & Plastics 0.8 1.1 0.3 -3.5 0.5 1.4 1.8 Specialty Chemicals & -0.4 -2.2 -1.8 -2.1 1.4 -0.6 -0.4 Products P
Slide 10: Non Operating Items
10 Non Operating Items - FY2014 Consolidated Results - （Billion Yen） FY2013 FY2014 Change Item (A) (B) (B) - (A) Operating income 24.4 24.1 -0.2 Net interest expense -2.0 -1.4 0.6 Equity in earnings of Non operating income unconsolidated subsidiaries -0.0 1.5 1.5 and affiliated companies Foreign cur
Slide 11: Extraordinary Items
11 Extraordinary Items - FY2014 Consolidated Results - （Billion Yen） FY2013 FY2014 Change Item (A) (B) (B) - (A) Gain on insurance claim - 3.8 3.8 Gain on negative goodwill 2.8 0.2 -2.6 ＊1 Loss on disposal of PP&E -0.7 -2.7 -2.0 Loss on impairment -0.1 (※) -1.5 -1.4 Loss on business of subsidiaries
Slide 12: Operating Income - Net Income
12 Operating Income - Net Income - FY2014 Consolidated Results - （Billion Yen） FY2013 FY2014 Change Item (A) (B) (B) - (A) Operating income 24.4 24.1 -0.2 Non operating item -5.7 -0.9 4.8 Ordinary income 18.6 23.2 4.5 Extraordinary item 0.9 -4.7 -5.7 Income before income tax and minority interest 19
Slide 13: Consolidated Balance Sheet
13 Consolidated Balance Sheet - FY2014 Consolidated Results - （Billion Yen） End of FY2013 End of FY2014 Change Item (A) (B) (B) - (A) Current assets 296.5 282.8 -13.7 Fixed assets 404.0 428.5 24.5 Total assets 700.7 711.5 10.8 Interest-bearing debts 245.8 239.7 -6.0 Other liabilities 189.5 182.2 -7.
Slide 14: Consolidated Statements of Cash Flows
14 Consolidated Statements of Cash Flows - FY2014 Consolidated Results - （Billion Yen） Item FY2013 FY2014 Losses before income tax and minority interests 18.4, A.Cash flows from operating activities 37.0 62.1 Depreciation and amortization 33.5, Working capital 8.4, etc. B.Cash flows from investing a
Slide 15: FY2015 Consolidated Forecasts
15 FY2015 Consolidated Forecasts
Slide 16: Scope of Consolidation
16 Scope of Consolidation - FY2015 Consolidated Forecasts - End of End of Change Item FY2014 FY2015 Notes (A) (B) （B) - （A) Number of First half： consolidated 71 71 0 + Sanshin Tsusho - AET (USA) LLC (※) subsidiaries Number of First half： equity method 24 25 1 + LOTTE UBE Synthetic Rubber affiliates
Slide 17: Material Price Environmental Factors
17 Environmental Factors - FY2015 Consolidated Forecasts - （Billion Yen) Impacts on FY2014 FY2015 Change Item Consolidated (A) (B) (B) - (A) OP Income Exchange Rate Yen/$ 109.9 120.0 10.1 0.5 (CIF) $/ｔ 820 600 -220 4.2 Naphtha (Domestic) (3.0) Yen/KL 63,400 52,000 -11,400 Material Price Benzene(ACP)
Slide 18: Major P/L & B/S Items
18 Major P/L ＆ B/S Items - FY2015 Consolidated Forecasts - （Billion Yen） FY2014 FY2015 Change Item (A) (B) (B) - (A) Sales 641.7 685.0 43.3 Operating income 24.1 36.0 11.9 Ordinary income 23.2 32.0 8.8 Profit attributable to owners of parent 14.6 17.0 2.4 End of FY2014 End of FY2015 Change Item (A)
Slide 19: Sales by Segment
19 Sales by Segment - FY2015 Consolidated Forecasts - （Billion Yen） FY2014 FY2015 Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain -0.9, Synthetic rubber 1.5, Chemicals 280.1 292.0 11.9 Battery Materials and Fine Chemicals 8.4, Polyimide and Specialty Products 3.5, etc Pharmace
Slide 20: Operating Income by Segment
20 Operating Income by Segment - FY2015 Consolidated Forecasts - （Billion Yen） FY2014 FY2015 Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain 7.2, Synthetic rubber -0.7, Chemicals -0.9 9.5 10.4 Battery Materials and Fine Chemicals 2.3, Polyimide and Specialty Products 1.8, etc
Slide 21: Analysis of Operating Income
21 Analysis of Operating Income - FY2015 Consolidated Forecasts - （Billion Yen） Operating Income Segment Change FY2014 FY2015 Sales Fixed Price Others (A) (B) (B) - (A) *1 Volume Cost *2 Chemicals -0.9 9.5 10.4 1.8 6.9 -0.8 2.4 Pharmaceutical 0.9 1.5 0.6 0.1 -0.2 -0.3 1.0 Cement & Construction 17.0
Slide 22: Operating Income - Net Income
22 Operating Income - Net Income - FY2015 Consolidated Forecasts - . （Billion Yen） FY2014 FY2015 Change Item (A) (B) (B) - (A) Operating income 24.1 36.0 11.9 Non operating item -0.9 -4.0 -3.1 Ordinary income 23.2 32.0 8.8 Extraordinary item -4.7 -7.0 -2.3 Income before income tax and minority inter
Slide 23: Appendix
23 Appendix UBE
Slide 24: Reference: FY2014 Sales / Operating Income by Segment
24 【Reference】 FY2014 Consolidated Results - Sales / Operating Incom by Segment - （Billion Yen） Sales Operating income Segment First half Second half Total First half Second half Total Chemicals 134.1 146.0 280.1 -3.3 2.4 -0.9 Pharmaceutical 3.5 4.2 7.8 0.4 0.4 0.9 Cement & Construction Materials 10
Slide 25: Reference: FY2015 Sales / Operating Income by Segment
25 【Reference】 FY2015 Consolidated Forecasts - Sales / Operating Incom by Segment - （Billion Yen） Sales Operating income Segment First half Second half Total First half Second half Total Chemicals 140.5 151.5 292.0 2.0 7.5 9.5 Pharmaceutical 3.5 6.0 9.5 0.5 1.0 1.5 Cement & Construction Materials 11
Slide 26: FY2015 Major Items for Capital Expenditure
26 FY2015 Major Items for Capital Expenditure Estimeated Segment Subject Place completion date Chemicals Nylon6 expansion Spain FY2018 PCD plant, New Facilities Thailand FY2015 Cement & Construction Waste heat power generation Materials Kanda, Japan FY2015 equipment Development of Kanayamadai Isa, J
Slide 27: Major Subsidiaries
27 Major Subsidiaries - FY2014 Consolidated Results - (Billion Yen) Operating Sales income Subsidiaries and Affiliates Business change from FY2014 FY2013 UBE CHEMICALS (ASIA) PUBLIC CO., LTD Manufacture and sales of caprolactam and polyamide resin 42.0 ↓ Manufacture and sales of caprolactam, ammoniu
Slide 28: Reference: Major data
28 【Reference】 Major data - FY2014 Consolidated Results - (Billion Yen) FY2015 Item FY2013 FY2014 Forecast capital investment 36.3 42.5 38.0 Depreciation andamortization 32.4 33.5 36.5 R&D expense 13.9 13.8 14.5 Adjusted operating profit 25.2 26.6 37.5 Debt 245.8 239.7 222.0 Net debt 215.7 202.7 195
Slide 29: Forward-looking statements disclaimer
29 This presentation material contains forward-looking statements concerning UBE’s future plans, strategies, and performance. These forward-looking statements are not historical facts; rather, they represent assumptions and beliefs based on economic, financial, and competitive date currently availab